Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 5/20 | 0.50 |
| ▸ | RXRA | P19793 | 4/20 | 0.50 |
| ▸ | RXRG | P48443 | 4/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28813907 | 0.92 | RXRB (0.46) | RXRBRXRARXRGMAPK8ALDH1A1 | |
| SCHEMBL27969759 | 0.90 | RXRB (0.45) | RXRBRXRARXRGMAPK8ALDH1A1 | |
| SCHEMBL2728852 | 0.84 | RXRB (0.67) | RXRBRXRARXRGALDH1A1NPC1 | |
| SCHEMBL26007734 | 0.83 | RXRB (0.50) | RXRBRXRARXRGMAPK8ALDH1A1 | |
| SCHEMBL14627632 | 0.83 | RXRB (0.50) | RXRBRXRARXRGALDH1A1NPC1 | |
| SCHEMBL658778 | 0.82 | MAPK8 (0.55) | RXRBRXRARXRGMAPK8ALDH1A1 | |
| SCHEMBL31339549 | 0.82 | MAPK8 (0.55) | RXRBRXRARXRGMAPK8ALDH1A1 | |
| SCHEMBL11111979 | 0.82 | RXRB (0.64) | RXRBRXRARXRGALDH1A1NPC1 | |
| SCHEMBL11208311 | 0.81 | CYP1A2 (0.49) | RXRBRXRARXRGALDH1A1NPC1 | |
| SCHEMBL16526945 | 0.80 | MAPK8 (0.54) | MAPK8ALDH1A1MAPTSMN1; SMN2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1243723-C | N-phenylpropylcyclopentyl substituted glutaramide derivatives as NEP inhibitors of FSAD | PFIZER LTD (US) | 2006-03-01 | — | — | CN | disclosed |
| US-6849649-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| CN-1492852-A | N-phenylpropylcyclopentyl substituted glutaramide derivatives as NEP inhibitors of FSAD | ������ҩ������˾ | 2004-04-28 | — | — | CN | disclosed |
| EP-1373192-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6660756-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002079143-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | RXRB 3258/4885RXRA 3291/4885RXRG 3479/4885 |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | RXRB 2690/4885RXRA 2811/4885RXRG 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.